Warticon (Podophyllotoxin)

What is Warticon?

Warticon (podophyllotoxin 0.15% cream) is a prescription topical antimitotic medicine used to treat external genital warts (any perianal use requires checking the exact product indication) (condylomata acuminata) caused by the human papillomavirus (HPV). It belongs to the same therapeutic class as Condyline (podophyllotoxin 0.5% solution), differing in its cream formulation and concentration.

Podophyllotoxin, the active ingredient, is a purified plant-derived cytotoxic agent that works by destroying the rapidly dividing cells of HPV-induced warts. Warticon cream is designed for patient self-application as part of a structured treatment cycle.

How does Warticon work?

Podophyllotoxin’s mechanism of action is well characterised as an antimitotic agent:

• Tubulin binding: Podophyllotoxin binds to the protein tubulin, specifically at the colchicine-binding site on the beta-tubulin subunit.
• Microtubule disruption: This binding prevents the polymerisation of tubulin into microtubules, which form the mitotic spindle — the cellular machinery essential for chromosome separation during cell division.
• Mitotic arrest: Without a functional spindle, dividing cells are arrested in the G2/M phase of the cell cycle (just before or during division), unable to complete mitosis.
• Cell necrosis: Cells arrested in mitosis undergo necrosis (death), leading to progressive destruction of the wart tissue over the treatment cycles.

The cream formulation of Warticon differs from the solution (Condyline) in that the vehicle (cream base) allows the active ingredient to remain at the site of application for longer and may penetrate wart tissue in a more controlled manner, potentially reducing the risk of spreading to surrounding healthy skin compared to a liquid solution.

Who is Warticon for?

Warticon cream is suitable for adults with confirmed or clinically assessed external genital warts (any perianal use requires checking the exact product indication) who are able to identify the wart tissue clearly and apply the cream accurately.

Particularly appropriate when:

• Warts are located in areas where cream application is easier to control than a liquid solution (e.g., moist perigenital areas)
• The patient finds the cream formulation easier to apply than a solution applicator
• The doctor has assessed that a cream formulation is preferable based on wart characteristics

Warticon is NOT suitable for:

• Pregnant women: Contraindicated due to teratogenic risk
• Internal warts: The cream should not be applied inside the vagina, urethra, or rectum
• Children under 18: Safety not established for this indication
• Large wart areas: More than 4 cm² requires direct professional supervision with the Spanish cream. The earlier reference to 50 separate warts is not a safe self-treatment limit
• Immunocompromised patients: May be less effective and can cause more severe local reactions — specialist input is advisable

Dosage and Application

Treatment schedule: Apply the cream to each wart twice daily (morning and evening) for 3 consecutive days. Then stop for 4 days. This completes one treatment cycle. Repeat for up to 4 cycles if needed.

Application instructions:

1. Clean and dry the treatment area before application.
2. Apply a small amount of cream precisely to each wart surface using the finger or applicator provided. Avoid healthy surrounding skin.
3. Allow the cream to dry and absorb before dressing.
4. Wash hands thoroughly after application.
5. Avoid sexual intercourse while the cream is on the skin.
6. Do not occlude the area with airtight dressings.

Amount per application: Use only enough cream to cover each wart. The earlier 0.5 mL / 10 cm² statement must not be used as a self-treatment limit; the Spanish 0.15% cream requires direct professional supervision above 4 cm².

Side effects

Local skin reactions can occur; they do not prove treatment success. Severity depends on the amount applied and individual sensitivity.

Very common side effects

• Burning, stinging, or pain at the treatment site
• Redness (erythema) of wart tissue
• Itching at the application site
• Erosion or superficial ulceration of wart tissue

Common side effects

• Inflammation of surrounding skin (if the cream contacts healthy tissue)
• Tenderness or soreness

Less common side effects

• Blistering at or near the treatment site
• Pigmentation changes (may be persistent)
• Drying or scaling of treated area

If severe pain, extensive inflammation, or open sores develop, stop treatment and consult a doctor. Seek medical advice before restarting treatment.

Systemic effects

Systemic absorption from topical application at recommended doses is minimal. However, if the cream is used on excessively large areas or more frequently than recommended, systemic toxicity (nausea, vomiting, neurological effects) may occur. Adhere strictly to prescribed amounts.

Warticon vs alternative wart treatments

Warticon vs Condyline: Both contain podophyllotoxin. The doctor must select the product, taking account of its formulation and approved instructions. Follow the instructions for the prescribed product and do not interchange these preparations on your own. Do not apply either preparation to mucous membranes.

Warticon vs Aldara: Podophyllotoxin (Warticon) works by direct tissue destruction, while imiquimod (Aldara) stimulates the immune system. Podophyllotoxin is generally faster-acting, while imiquimod may have lower recurrence rates due to its immunostimulatory effect. Clinical selection depends on individual assessment by a doctor.

Online assessment for Warticon (Podophyllotoxin)

Warticon is a prescription-only medicine (POM) in all EU member states. It cannot legally be dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicines, employ doctors, or sell medicines. Our platform connects patients with independent doctors who can conduct confidential online health assessments.

Availability of an online assessment, prescribing, dispensing and delivery depends on the medicine, country and applicable law. Spain prohibits distance sale of prescription medicines; a catalogue entry or cross-border prescription does not establish a right to delivery. An in-person examination or testing may be required.

The process, where legally and clinically available:

1. Complete a health assessment: Describe the warts — their size, number, location, and duration — along with your sexual health history and any previous wart treatments.
2. Doctor review: An independent doctor reviews your assessment. If Warticon cream is clinically appropriate, they may issue a prescription.
3. Pharmacy fulfilment: The prescription is sent to a pharmacy partner to assess dispensing and any supply under the applicable country rules.

Important: Prescrivia does not guarantee that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals.

Important safety information

Do not use Warticon if you:

• Are pregnant or trying to become pregnant
• Are breastfeeding
• Are under 18 years of age
• Are allergic to podophyllotoxin or any ingredient in the cream
• Have open, inflamed, or bleeding skin in the intended treatment area

Tell your doctor if you:

• Are immunocompromised (including HIV-positive or on immunosuppressant treatment)
• Have previously used any other wart treatment (including cryotherapy or Aldara)
• Are uncertain whether your lesions are genital warts — other conditions including vulval intraepithelial neoplasia (VIN), molluscum contagiosum, and skin cancers can resemble genital warts and must be excluded

Latex contraception: Podophyllotoxin cream may affect latex condoms and diaphragms. Avoid unprotected sexual contact during treatment.

HPV and recurrence: Treating visible warts removes the physical lesions but does not eliminate the underlying HPV infection. Warts may recur after successful treatment. The virus can be transmitted to sexual partners even when no visible warts are present.

Sources

• Product information / clinical reference 1
• Irish Condyline 5 mg/mL solution, HPRA document dated 31 May 2021

Medical information on this page is based on the following sources:

• World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer — Fact sheet. who.int
• Lacey CJ, et al. 2012 European guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology. 2013;27(3):e28–35.

The content-edit date does not certify a clinical review. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.